Regeneron Pharmaceuticals, Inc.
Anti-CTLA-4 antibodies and uses thereof
Last updated:
Abstract:
The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
Status:
Grant
Type:
Utility
Filling date:
26 Jul 2018
Issue date:
24 Nov 2020